Both Mashatile and Motsoaledi have repeatedly lamented, correctly, the severe reliance of our health system on external donors, but have not acknowledged that they have been fully responsible for the ...

A new study explores how healthcare providers can effectively implement Apretude for HIV pre-exposure prophylaxis (PrEP) ...

Proposed Medicaid cuts could threaten lifesaving HIV treatment access, warns Avenue 360. HOUSTON — With President Trump's " ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for cabotegravir, allowing it to be produced by three generic drugmakers and supplied to ...

The Senate is poised to vote this week on President Donald Trump's rescissions package requesting roughly $9.4 billion in ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

The World Health Organization has approved the rollout of an injectable HIV preventive drug; Lenacapavir or LEN. The National ...